Fulcrum Therapeutics (FULC) EBITDA (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly EBITDA of -$29.3 million for Q2 2026, down 47.92% year-over-year from -$56.3 million in Q2 2025, and down 32.11% quarter-over-quarter from -$22.2 million in Q1 2026.
Fulcrum Therapeutics (FULC) EBITDA (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported EBITDA for 9 consecutive years, with -$29.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBITDA fell 47.92% year-over-year to -$29.3 million; the TTM figure through Jun 2026 stood at -$96.0 million (down 13.3% YoY), while the FY2025 annual figure was -$84.8 million, down 287.13% from the prior year.
- EBITDA slipped to -$29.3 million in Q2 2026 per FULC's latest filing, from -$22.2 million in the prior quarter.
- Across five years, EBITDA topped out at $52.5 million in Q2 2024 and bottomed at -$34.2 million in Q2 2022.
- Historically, EBITDA has averaged -$21.2 million across 5 years, with a median of -$25.6 million in 2022.
- Annual changes were most pronounced in 2024 — EBITDA jumped 292.33% — and 2025, when it tumbled 137.75%.
- Fulcrum Therapeutics' EBITDA stood at -$28.0 million in 2022, then slipped by 0.07% to -$28.0 million in 2023, then jumped by 30.59% to -$19.4 million in 2024, then retreated by 16.8% to -$22.7 million in 2025, then declined by 29.16% to -$29.3 million in 2026.
- Business Quant data shows FULC's EBITDA at -$29.3 million in Q2 2026, -$22.2 million in Q1 2026, and -$22.7 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | -29.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -29.31 Mn |
| Mar 31, 2026 | -22.19 Mn |
| Dec 31, 2025 | -22.69 Mn |
| Sep 30, 2025 | -21.86 Mn |
| Jun 30, 2025 | -19.82 Mn |
| Mar 31, 2025 | -20.40 Mn |
| Dec 31, 2024 | -19.43 Mn |
| Sep 30, 2024 | -25.13 Mn |
| Jun 30, 2024 | 52.49 Mn |
| Mar 31, 2024 | -29.83 Mn |
| Dec 31, 2023 | -27.99 Mn |
| Sep 30, 2023 | -27.44 Mn |
| Jun 30, 2023 | -27.29 Mn |
| Mar 31, 2023 | -27.94 Mn |
| Dec 31, 2022 | -27.97 Mn |
| Sep 30, 2022 | -24.36 Mn |
| Jun 30, 2022 | -34.24 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -23.56 Mn |
| Sep 30, 2021 | -20.77 Mn |